Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Net Income towards Common Stockholders: 2016-2025

Historic Net Income towards Common Stockholders for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $31.5 million.

  • Collegium Pharmaceutical's Net Income towards Common Stockholders rose 237.51% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.4 million, marking a year-over-year decrease of 34.03%. This contributed to the annual value of $42.4 million for FY2024, which is 7.88% down from last year.
  • Per Collegium Pharmaceutical's latest filing, its Net Income towards Common Stockholders stood at $31.5 million for Q3 2025, which was up 162.93% from $12.0 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Net Income towards Common Stockholders registered a high of $74.0 million during Q2 2021, and its lowest value of -$25.0 million during Q4 2021.
  • In the last 3 years, Collegium Pharmaceutical's Net Income towards Common Stockholders had a median value of $13.0 million in 2023 and averaged $14.8 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Net Income towards Common Stockholders slumped by 459.79% in 2021, and later soared by 4,415.10% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Net Income towards Common Stockholders (Quarterly) stood at -$25.0 million in 2021, then skyrocketed by 71.24% to -$7.2 million in 2022, then spiked by 543.67% to $31.9 million in 2023, then plummeted by 60.75% to $12.5 million in 2024, then skyrocketed by 237.51% to $31.5 million in 2025.
  • Its Net Income towards Common Stockholders stands at $31.5 million for Q3 2025, versus $12.0 million for Q2 2025 and $2.4 million for Q1 2025.